<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459907</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>The Trajectory of Antibody Responses One Year Following SARS-CoV-2 Infection among Indigenous Individuals in the Southwest United States.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1573</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101573</ELocationID><Abstract><AbstractText>SARS-CoV-2 antibody kinetics based on immunologic history is not fully understood. We analyzed anti-spike and anti-nucleocapsid antibody responses following acute infection in a cohort of Indigenous persons. The models of peak concentrations and decay rates estimated that one year after infection, participants would serorevert for anti-nucleocapsid antibodies and remain seropositive for anti-spike antibodies. The peak anti-spike concentrations were higher for individuals vaccinated prior to infection, but the decay rates were similar across immunologic status groups. Children had significantly lower peak anti-spike concentrations than adults. This study affirms the importance of continued vaccination to maintain high levels of immunity in the face of waning immunity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Claire P</ForeName><Initials>CP</Initials><Identifier Source="ORCID">0000-0003-1069-9460</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Rachel M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0002-6837-4629</Identifier><AffiliationInfo><Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kugler</LastName><ForeName>Alexa M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Little</LastName><ForeName>Verlena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Owen R</ForeName><Initials>OR</Initials><Identifier Source="ORCID">0009-0006-0728-6509</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fairlie</LastName><ForeName>Tarayn A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0001-9954-7185</Identifier><AffiliationInfo><Affiliation>Division of Coronaviruses and Other Respiratory Viruses, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Reinaldo E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Melissa B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Division of Coronaviruses and Other Respiratory Viruses, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honie</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laeyendecker</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-6429-4760</Identifier><AffiliationInfo><Affiliation>Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Midgley</LastName><ForeName>Claire M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Division of Coronaviruses and Other Respiratory Viruses, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Dennie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandoval</LastName><ForeName>Marqia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Saki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammitt</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutcliffe</LastName><ForeName>Catherine G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0001-8512-8326</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>75D30120C08171</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015206" MajorTopicYN="N" Type="Geographic">Southwestern United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081034" MajorTopicYN="N">Indigenous Peoples</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Indigenous health</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody response</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funder was involved in the design of the study; interpretation of data; in the writing of the manuscript; and in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459907</ArticleId><ArticleId IdType="pmc">PMC11512241</ArticleId><ArticleId IdType="doi">10.3390/v16101573</ArticleId><ArticleId IdType="pii">v16101573</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 7 June 2023)].  Available online:  https://covid19.who.int.</Citation></Reference><Reference><Citation>Jones J.M., Manrique I.M., Stone M.S., Grebe E., Saa P., Germanio C.D., Spencer B.R., Notari E., Bravo M., Lanteri M.C., et al. Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status—United States, April 2021–September 2022. MMWR. 2023;72:601–605. doi: 10.15585/mmwr.mm7222a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7222a3</ArticleId><ArticleId IdType="pmc">PMC10243484</ArticleId><ArticleId IdType="pubmed">37262007</ArticleId></ArticleIdList></Reference><Reference><Citation>Olmstead A.D., Nikiforuk A.M., Schwartz S., Marquez A.C., Valadbeigy T., Flores E., Saran M., Goldfarb D.M., Hayden A., Masud S., et al. Characterizing longitudinal antibody responses in recovered individuals following COVID-19 infection and single-dose vaccination: A prospective cohort study. Viruses. 2022;14:2416. doi: 10.3390/v14112416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112416</ArticleId><ArticleId IdType="pmc">PMC9694471</ArticleId><ArticleId IdType="pubmed">36366515</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanshylla K., Di Cristanziano V., Kleipass F., Dewald F., Schommers P., Gieselmann L., Gruell H., Schlotz M., Ercanoglu M.S., Stumpf R., et al. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell Host Microbe. 2021;29:917–929.e914. doi: 10.1016/j.chom.2021.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.04.015</ArticleId><ArticleId IdType="pmc">PMC8090990</ArticleId><ArticleId IdType="pubmed">33984285</ArticleId></ArticleIdList></Reference><Reference><Citation>Gluck V., Grobecker S., Kostler J., Tydykov L., Bertok M., Weidlich T., Gottwald C., Salzberger B., Wagner R., Zeman F., et al. Immunity after COVID-19 and vaccination: Follow-up study over 1 year among medical personnel. Infection. 2022;50:439–446. doi: 10.1007/s15010-021-01703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01703-9</ArticleId><ArticleId IdType="pmc">PMC8475821</ArticleId><ArticleId IdType="pubmed">34562263</ArticleId></ArticleIdList></Reference><Reference><Citation>den Hartog G., Vos E.R.A., van den Hoogen L.L., van Boven M., Schepp R.M., Smits G., van Vliet J., Woudstra L., Wijmenga-Monsuur A.J., van Hagen C.C.E., et al. Persistence of antibodies to severe acute respiratory syndrome coronavirus 2 in relation to symptoms in a nationwide prospective study. Clin. Infect. Dis. 2021;73:2155–2162. doi: 10.1093/cid/ciab172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab172</ArticleId><ArticleId IdType="pmc">PMC7929058</ArticleId><ArticleId IdType="pubmed">33624751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley S.F., Wei J., O’Donnell D., Stoesser N.E., Matthews P.C., Howarth A., Hatch S.B., Marsden B.D., Cox S., James T., et al. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin. Infect. Dis. 2021;73:e699–e709. doi: 10.1093/cid/ciab004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab004</ArticleId><ArticleId IdType="pmc">PMC7929225</ArticleId><ArticleId IdType="pubmed">33400782</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N. Engl. J. Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok S.L., Cheng S.M., Leung J.N., Leung K., Lee C.K., Peiris J.M., Wu J.T. Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. Euro Surveill. 2022;27:2101197. doi: 10.2807/1560-7917.ES.2022.27.2.2101197.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.2.2101197</ArticleId><ArticleId IdType="pmc">PMC8759113</ArticleId><ArticleId IdType="pubmed">35027105</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates T.A., McBride S.K., Leier H.C., Guzman G., Lyski Z.L., Schoen D., Winders B., Lee J.Y., Lee D.X., Messer W.B., et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci. Immunol. 2022;7:eabn8014. doi: 10.1126/sciimmunol.abn8014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abn8014</ArticleId><ArticleId IdType="pmc">PMC8939472</ArticleId><ArticleId IdType="pubmed">35076258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Muecksch F., Schaefer-Babajew D., Finkin S., Viant C., Gaebler C., Hoffmann H.H., Barnes C.O., Cipolla M., Ramos V., et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595:426–431. doi: 10.1038/s41586-021-03696-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03696-9</ArticleId><ArticleId IdType="pmc">PMC8277577</ArticleId><ArticleId IdType="pubmed">34126625</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID-19 Hospitalization and Death by Race/Ethnicity.  [(accessed on 16 September 2024)]; Available online:  https://archive.cdc.gov/#/details?url=https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html.</Citation></Reference><Reference><Citation>Haroz E.E., Kemp C.G., O’Keefe V.M., Pocock K., Wilson D.R., Christensen L., Walls M., Barlow A., Hammitt L. Nurturing innovation at the roots: The success of COVID-19 vaccination in American Indian and Alaska Native communities. Am. J. Public. Health. 2022;112:383–387. doi: 10.2105/AJPH.2021.306635.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2021.306635</ArticleId><ArticleId IdType="pmc">PMC8887173</ArticleId><ArticleId IdType="pubmed">35196058</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackey K., Ayers C.K., Kondo K.K., Saha S., Advani S.M., Young S., Spencer H., Rusek M., Anderson J., Veazie S., et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: A systematic review. Ann. Intern. Med. 2021;174:362–373. doi: 10.7326/M20-6306.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-6306</ArticleId><ArticleId IdType="pmc">PMC7772883</ArticleId><ArticleId IdType="pubmed">33253040</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores L.E., Frontera W.R., Andrasik M.P., Del Rio C., Mondriguez-Gonzalez A., Price S.A., Krantz E.M., Pergam S.A., Silver J.K. Assessment of the inclusion of racial/ethnic minority, female, and older individuals in vaccine clinical trials. JAMA Netw. Open. 2021;4:e2037640. doi: 10.1001/jamanetworkopen.2020.37640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.37640</ArticleId><ArticleId IdType="pmc">PMC7896193</ArticleId><ArticleId IdType="pubmed">33606033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C. Characterizing the COVID-19 Pandemic among Indigenous Persons in the United States: COVID-19 Burden, SARS-CoV-2 Vaccine Effectiveness, and Risk Factors for Severe Disease and Post COVID-19 Conditions. Johns Hopkins University; Baltimore, MD, USA: 2023.</Citation></Reference><Reference><Citation>Meso Scale Discovery  . V-PLEX COVID-19 Serology Assays Insert. Meso Scale Diagnostics, LLC.; Rockville, MD, USA: 2022.  [(accessed on 18 December 2023)].  Available online:  https://www.mesoscale.com/~/media/files/product%20inserts/v-plex%20covid-19%20serology%20assays%20insert.pdf.</Citation></Reference><Reference><Citation>Kristiansen P.A., Page M., Bernasconi V., Mattiuzzo G., Dull P., Makar K., Plotkin S., Knezevic I. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397:1347–1348. doi: 10.1016/S0140-6736(21)00527-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00527-4</ArticleId><ArticleId IdType="pmc">PMC7987302</ArticleId><ArticleId IdType="pubmed">33770519</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  People with Certain Medical Conditions.  [(accessed on 18 December 2023)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#:~:text=Like%20adults%2C%20children%20with%20obesity,on%20vaccination%20information%20for%20children.</Citation></Reference><Reference><Citation>Lambrou A.S., Shirk P., Steele M.K., Paul P., Paden C.R., Cadwell B., Reese H.E., Aoki Y., Hassell N., Zheng X.Y., et al. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants—United States, June 2021–January 2022. MMWR. 2022;71:206–211. doi: 10.15585/mmwr.mm7106a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7106a4</ArticleId><ArticleId IdType="pmc">PMC8830620</ArticleId><ArticleId IdType="pubmed">35143464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M.I.M., Diepers P., Janke C., Plank M., Eser T.M., Rubio-Acero R., Fuchs A., Baranov O., Castelletti N., Kroidl I., et al. Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections. Front. Immunol. 2022;13:1026473. doi: 10.3389/fimmu.2022.1026473.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1026473</ArticleId><ArticleId IdType="pmc">PMC9792977</ArticleId><ArticleId IdType="pubmed">36582222</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado J.F., Vidal-Pla M., Moya M.C., Espasa M., Casabella A., Seda M., Calvet J., Gratacos J., Serrano R.M., Pena P. SARS-CoV-2 spike protein vaccine-induced immune imprinting reduces nucleocapsid protein antibody response in SARS-CoV-2 infection. J. Immunol. Res. 2022;2022:8287087. doi: 10.1155/2022/8287087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/8287087</ArticleId><ArticleId IdType="pmc">PMC9355782</ArticleId><ArticleId IdType="pubmed">35935586</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Elslande J., Oyaert M., Lorent N., Vande Weygaerde Y., Van Pottelbergh G., Godderis L., Van Ranst M., Andre E., Padalko E., Lagrou K., et al. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diag Microbiol. Infect. Dis. 2022;103:115659. doi: 10.1016/j.diagmicrobio.2022.115659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2022.115659</ArticleId><ArticleId IdType="pmc">PMC8837483</ArticleId><ArticleId IdType="pubmed">35278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Legros V., Denolly S., Vogrig M., Boson B., Siret E., Rigaill J., Pillet S., Grattard F., Gonzalo S., Verhoeven P., et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol. Immunol. 2021;18:318–327. doi: 10.1038/s41423-020-00588-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00588-2</ArticleId><ArticleId IdType="pmc">PMC7786875</ArticleId><ArticleId IdType="pubmed">33408342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley S.F., O’Donnell D., Stoesser N.E., Matthews P.C., Howarth A., Hatch S.B., Marsden B.D., Cox S., James T., Warren F., et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N. Engl. J. Med. 2021;384:533–540. doi: 10.1056/NEJMoa2034545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034545</ArticleId><ArticleId IdType="pmc">PMC7781098</ArticleId><ArticleId IdType="pubmed">33369366</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisberg S.P., Connors T.J., Zhu Y., Baldwin M.R., Lin W.H., Wontakal S., Szabo P.A., Wells S.B., Dogra P., Gray J., et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 2021;22:25–31. doi: 10.1038/s41590-020-00826-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00826-9</ArticleId><ArticleId IdType="pmc">PMC8136619</ArticleId><ArticleId IdType="pubmed">33154590</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce C.A., Preston-Hurlburt P., Dai Y., Aschner C.B., Cheshenko N., Galen B., Garforth S.J., Herrera N.G., Jangra R.K., Morano N.C., et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci. Transl. Med. 2020;12:eabd5487. doi: 10.1126/scitranslmed.abd5487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd5487</ArticleId><ArticleId IdType="pmc">PMC7658796</ArticleId><ArticleId IdType="pubmed">32958614</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunyavanich S., Do A., Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323:2427–2429. doi: 10.1001/jama.2020.8707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.8707</ArticleId><ArticleId IdType="pmc">PMC7240631</ArticleId><ArticleId IdType="pubmed">32432657</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer B., Knabbe C., Vollmer T. Analysis of a German blood donor cohort reveals a high number of undetected SARS-CoV-2 infections and sex-specific differences in humoral immune response. PLoS ONE. 2022;17:e0279195. doi: 10.1371/journal.pone.0279195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0279195</ArticleId><ArticleId IdType="pmc">PMC9757571</ArticleId><ArticleId IdType="pubmed">36525449</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T., Ellingson M.K., Wong P., Israelow B., Lucas C., Klein J., Silva J., Mao T., Oh J.E., Tokuyama M., et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315–320. doi: 10.1038/s41586-020-2700-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2700-3</ArticleId><ArticleId IdType="pmc">PMC7725931</ArticleId><ArticleId IdType="pubmed">32846427</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallais F., Gantner P., Bruel T., Velay A., Planas D., Wendling M.J., Bayer S., Solis M., Laugel E., Reix N., et al. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine. 2021;71:103561. doi: 10.1016/j.ebiom.2021.103561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103561</ArticleId><ArticleId IdType="pmc">PMC8390300</ArticleId><ArticleId IdType="pubmed">34455390</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington W.E., Trakhimets O., Andrade D.V., Dambrauskas N., Raappana A., Jiang Y., Houck J., Selman W., Yang A., Vigdorovich V., et al. Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. Cell Rep. Med. 2021;2:100253. doi: 10.1016/j.xcrm.2021.100253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100253</ArticleId><ArticleId IdType="pmc">PMC8020863</ArticleId><ArticleId IdType="pubmed">33842901</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterlin D., Mathian A., Miyara M., Mohr A., Anna F., Claer L., Quentric P., Fadlallah J., Devilliers H., Ghillani P., et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 2021;13:eabd2223. doi: 10.1126/scitranslmed.abd2223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd2223</ArticleId><ArticleId IdType="pmc">PMC7857408</ArticleId><ArticleId IdType="pubmed">33288662</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Clemens E.B., Kedzierski L., Chua B.Y., Mayo M., Lonzi C., Hinchcliff A., Rigas V., Middleton B.F., Binks P., et al. Broad spectrum SARS-CoV-2-specific immunity in hospitalized First Nations peoples recovering from COVID-19. Immunol. Cell Biol. 2023;101:964–974. doi: 10.1111/imcb.12691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12691</ArticleId><ArticleId IdType="pmc">PMC10872797</ArticleId><ArticleId IdType="pubmed">37725525</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Kedzierski L., Chua B.Y., Mayo M., Lonzi C., Rigas V., Middleton B.F., McQuilten H.A., Rowntree L.C., Allen L.F., et al. Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. Nat. Immunol. 2023;24:966–978. doi: 10.1038/s41590-023-01508-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01508-y</ArticleId><ArticleId IdType="pmc">PMC10232372</ArticleId><ArticleId IdType="pubmed">37248417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatcher S.M., Agnew-Brune C., Anderson M., Zambrano L.D., Rose C.E., Jim M.A., Baugher A., Liu G.S., Patel S.V., Evans M.E., et al. COVID-19 Among American Indian and Alaska Native Persons—23 States, 31 January–3 July 2020. MMWR. 2020;69:1166–1169. doi: 10.15585/mmwr.mm6934e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6934e1</ArticleId><ArticleId IdType="pmc">PMC7451969</ArticleId><ArticleId IdType="pubmed">32853193</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>